A phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancers.

Chairs
Dr. Sherene Loi, Peter MacCallum Cancer Center
Prof. Fabrice Andre, Institut Gustave Roussy

Statistician
Anita Giobbie-Hurder

Data Manager
Susan Fischer

Lead Trial Coordinator

Holly Shaw

Trial Monitors
Daniela Celotto, Carmen Comune, Magdalena Sánchez Hohl

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Date of Activation
May 9, 2014

Targeted Accrual
between 6 and 61 patients

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login